Phase II PASADENA Part one Week 52 results: Evaluating safety and efficacy of prasinezumab in early Parkinson's diseaseG. Pagano,K. Taylor,J. Anzures-Cabrera,W. Zago, R. Tripuraneni,T. Nikolcheva,H. Svoboda,J. Azulay,B. Mollenhauer,L. Lopez Manzanares,D. Russell,J. Boyd,A. Nicholas, M. Luquin,R. Hauser,T. Simuni,T. Gasser,W. Poewe,G. Kinney,R. Doody,P. Fontoura,D. Umbricht,A. BonniEUROPEAN JOURNAL OF NEUROLOGY（2021）引用 1|浏览24AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
